<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675090</url>
  </required_header>
  <id_info>
    <org_study_id>H3B109689</org_study_id>
    <nct_id>NCT00675090</nct_id>
  </id_info>
  <brief_title>Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease</brief_title>
  <official_title>A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a safety and tolerability study to investigate the effect of GSK239512 on mild to&#xD;
      moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the&#xD;
      most well tolerated dose in the patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2008</start_date>
  <completion_date type="Actual">June 16, 2009</completion_date>
  <primary_completion_date type="Actual">June 16, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.</measure>
    <time_frame>Days 8, 15, 22 and 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.</measure>
    <time_frame>days 8, 15, 22 and 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>GSK239512</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK239512 oral tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK239512</intervention_name>
    <description>GSK239512 oral tablets once a day</description>
    <arm_group_label>GSK239512</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets to match once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects with a clinical diagnosis of probable Alzheimer's disease&#xD;
&#xD;
          -  The subject has an MMSE score at screening of 12 to 26 for Part A and 16-26 for Part&#xD;
             B.&#xD;
&#xD;
          -  Age ≥ 50 and above.&#xD;
&#xD;
          -  If female, the subject must be post-menopausal (i.e. 12 months without menstrual&#xD;
             period) or surgically sterile.&#xD;
&#xD;
          -  Male subjects must be willing to abstain from sexual intercourse with pregnant or&#xD;
             lactating women; or be willing to use a condom/spermicide in addition to having their&#xD;
             female partner use another form of contraception if the woman could become pregnant,&#xD;
             from the time of the first dose of GSK239512 until 84 days following completion of the&#xD;
             study.&#xD;
&#xD;
          -  The subject has the ability to comply with the study procedures.&#xD;
&#xD;
          -  The subject has a permanent caregiver and is willing to attend all study visits for&#xD;
             Parts A and B.&#xD;
&#xD;
          -  The subject has provided full written informed consent prior to the performance of any&#xD;
             protocol specific procedure, or if unable to provide informed consent due to cognitive&#xD;
             status, full written informed consent on behalf of the subject has been provided by a&#xD;
             legally acceptable representative.&#xD;
&#xD;
          -  The caregiver has provided his / her written consent prior to the performance of any&#xD;
             protocol specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the investigator, following review of CT/MRI scans in the past 12&#xD;
             months and completion of neurological review there could be other probable causes of&#xD;
             dementia&#xD;
&#xD;
          -  History of significant psychiatric illness such as schizophrenia or bipolar affective&#xD;
             disorder that in the opinion of the Investigator would interfere with participation in&#xD;
             the study, or current depression (a score of ≥8 on the Cornell Scale for Depression in&#xD;
             Dementia), or subjects with other psychiatric features in their AD which would in the&#xD;
             opinion of the investigator, would increase risk to safety.&#xD;
&#xD;
          -  History of significant sleep disturbance, for example, when it is associated with&#xD;
             nocturnal wandering, nocturnal confusion / disorientation / agitation, which in the&#xD;
             opinion of the investigator, may increase safety risk.&#xD;
&#xD;
          -  History or presence of known or suspected seizures, unexplained significant loss of&#xD;
             consciousness within last 6 months. Subjects who had febrile seizures in childhood may&#xD;
             be included if these ceased by age 10 and they have had no other type of seizure in&#xD;
             their medical history and have not been on anti-epileptic medications.&#xD;
&#xD;
          -  History or presence of significant cardiovascular, gastro-intestinal, hepatic, or&#xD;
             renal disease or other condition known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of drugs, or any other clinically relevant abnormality,&#xD;
             medical or psychiatric condition, which, in the opinion of the Investigator, makes the&#xD;
             subject unsuitable for inclusion in the study.&#xD;
&#xD;
          -  History of alcohol or other substance abuse, according to the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders - Substance related disorders (DSM-IV)&#xD;
             criteria.&#xD;
&#xD;
          -  Clinically significant abnormalities in laboratory tests, including subjects with&#xD;
             active liver disease or uncontrolled thyroid disease.&#xD;
&#xD;
          -  Uncontrolled hypertension with systolic BP ≥160 and/or diastolic ≥95 mmHg. Subjects&#xD;
             with controlled hypertension with systolic BP &lt; 160 mmHg and diastolic &lt;95 mmHg for at&#xD;
             least 4 weeks are acceptable.&#xD;
&#xD;
          -  Systolic BP &lt;100 mmHg and/or diastolic &lt;60 mmHg.&#xD;
&#xD;
          -  Subjects with ECG criteria outside ranges specified in the protocol&#xD;
&#xD;
          -  History of hypersensitivity to GSK239512 or its excipients.&#xD;
&#xD;
          -  Treatment with cholinesterase inhibitors, (including Tacrine), memantine or selegiline&#xD;
             within the previous month. No patients with AD who are already on these medications at&#xD;
             the time of screening will be recruited, as it would be unethical to withdraw these&#xD;
             medications for study participation. Only AD subjects who are not yet on these&#xD;
             medications, or who have withdrawn from these medications for other reasons&#xD;
             previously, may be enrolled into this study.&#xD;
&#xD;
          -  Subjects who are currently taking or who have taken in the last month anti-psychotic&#xD;
             drugs (typical or atypical dopaminergic antagonists or modulators) or mood&#xD;
             stabilization drugs (including SSRI, DNRI, SNRI, MAO inhibitors, tricyclic&#xD;
             antidepressants, lithium, valproate, carbamazepine).&#xD;
&#xD;
          -  Subjects who are currently taking Pgp inhibitors or any CYP3A4 inhibitors.&#xD;
&#xD;
          -  Subjects on chronic sedative medications (≥ 4 days per week for the past 4 weeks).&#xD;
&#xD;
          -  Subject or caregiver is an immediate family member or employee of the participating&#xD;
             Investigator, any of the participating site staff or GSK staff.&#xD;
&#xD;
          -  Has received any other investigational treatment in the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg Heights</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Prague 10</city>
        <zip>10100</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridgeshire</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southall</city>
        <zip>UB1 3HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr Alzheimer Res. 2013 Mar;10(3):240-51.</citation>
    <PMID>23521503</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimers Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>H3B109689</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

